Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
| العنوان: | Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus |
|---|---|
| المؤلفون: | Barbara Katharina Geist, Helmut Brath, Lucia Zisser, Josef Yu, Barbara Fueger, Lukas Nics, Eva Maria Patronas, Alexandra Kautzky-Willer, Marcus Hacker, Sazan Rasul |
| المصدر: | European Journal of Nuclear Medicine and Molecular Imaging. |
| بيانات النشر: | Springer Science and Business Media LLC, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Radiology, Nuclear Medicine and imaging, General Medicine |
| الوصف: | Purpose Sodium-glucose cotransporter 2 inhibitor (SGLT2i) regulation, developed as treatment for patients with type 2 diabetes, can be imaged with the glucose analogue alpha-methyl-4-deoxy-4-[18F]fluoro-d-glucopyranoside (Me4FDG), a positron emission tomography (PET) tracer with a high affinity for SGLT1 and SGLT2 proteins. With regard to therapy effectiveness, we aimed to investigate whether clinical parameters or Me4FDG excretion could predict response to SGLT2i in patients with type 2 diabetes. Methods In a longitudinal, prospective study, 19 patients with type 2 diabetes underwent Me4FDG combined PET and magnetic resonance imaging (PET/MRI) scans at baseline and 2 weeks after initiation of therapy with SGLT2i, accompanied by the collection of blood and urine samples. Me4FDG-excretion was determined from the Me4FDG uptake in the bladder. Long-term response was determined by HbA1c level after 3 months; a strong response to the therapy was defined as a reduction of HbA1c by at least 10% from baseline. Results SGLT2i resulted in significantly increased Me4FDG excretion (4.8 vs. 45.0, P P r = 0.55 (P P = 0.005, OR 1.9). Conclusions Using Me4FDG-PET, we demonstrated for the first time renal SGLT2-related excretion before and after short-term SGLT2i treatment. In contrary to other clinical parameters, SGLT2-related excretion before treatment was a robust predictor of long-term HbA1c response in patients with type 2 diabetes, suggesting that therapy effectiveness is only dependent of endogenous SGLT2 processes. |
| تدمد: | 1619-7089 1619-7070 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::6ab29ce91506b7e5157515f3e30a30f2 https://doi.org/10.1007/s00259-023-06256-7 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........6ab29ce91506b7e5157515f3e30a30f2 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 16197089 16197070 |
|---|